Good Outcomes of Patients with Stage IB Endometrial Cancer with Surgery Alone

dc.contributor.authorRahatli, Samed
dc.contributor.authorDizdar, Omer
dc.contributor.authorKucukoztas, Nadire
dc.contributor.authorOguz, Arzu
dc.contributor.authorYalcin, Selim
dc.contributor.authorOzen, Ozlem
dc.contributor.authorReyhan, Nihan Haberal
dc.contributor.authorTarhan, Cagla
dc.contributor.authorYildiz, Ferah
dc.contributor.authorDursun, Polat
dc.contributor.authorAltundag, Ozden
dc.contributor.authorAyhan, Ali
dc.date.accessioned2019-12-19T13:23:00Z
dc.date.available2019-12-19T13:23:00Z
dc.date.issued2014
dc.description.abstractBackground: Most patients with endometrial cancer have stage I disease. Adjuvant therapy in stage IB (formerly IC) endometrial cancer is controversial, treatment options including observation or brachytherapy/radiotherapy in grade 1-3 patients with or without chemotherapy. The purpose of this study was to assess the outcomes of our patients with stage IB endometrioid endometrial cancer. Materials and Methods: Sixty two patients with stage IB endometrial cancer and endometrioid histology were retrospectively evaluated. All patients were initially treated surgically by the same surgeon with comprehensive staging, i.e. total abdominal hysterectomy, bilateral salphingooopherectomy, bilateral pelvic and paraaortic lymph node dissection and omentectomy. Adjuvant radiotherapy was discussed with patients and utilized by those who accepted. Adjuvant chemotherapy was not given to any of the patients. Results: Median age was 62 (range, 42-95). Ninety percent of the patients had grade 1-2 disease. Thirteen patients (21%) received intra vaginal brachytherapy (IVBT) and one received whole pelvic radiotherapy (WPRT). Median follow-up time was 46 months (range, 9-77 months). Three patients experienced recurrence (4.8%), two of them died on follow-up and one was still alive at last visit. Two patients with recurrence had FIGO grade 2 tumors and one had a grade 3 tumor. Two patients (3.2%) died without evidence of recurrent disease. Relapse free survival at 5 years was 94.4% and overall survival was 93.1%. Conclusions: Patients with stage IB disease in our study demonstrated relatively low recurrence rates with this stage of endometrial cancer.en_US
dc.identifier.endpage3893en_US
dc.identifier.issn1513-7368
dc.identifier.issue9en_US
dc.identifier.startpage3891en_US
dc.identifier.urihttp://koreascience.or.kr/article/JAKO201424635096053.page
dc.identifier.urihttp://hdl.handle.net/11727/4498
dc.identifier.volume15en_US
dc.identifier.wos000338634000007
dc.language.isoengen_US
dc.relation.isversionof10.7314/APJCP.2014.15.9.3891en_US
dc.relation.journalASIAN PACIFIC JOURNAL OF CANCER PREVENTIONen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEndometrial canceren_US
dc.subjectstage IBen_US
dc.subjectsurgeryen_US
dc.subjectchemotherapyen_US
dc.subjectradiotherapyen_US
dc.titleGood Outcomes of Patients with Stage IB Endometrial Cancer with Surgery Aloneen_US
dc.typearticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Good_Outcomes_of_Patients_with_Stage_IB_Endometrial_Cancer_with_Surgery_Alone.pdf
Size:
167.49 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: